世界卫生组织II级脑膜瘤次全切除术后辅助放疗的结局
回顾性分析1996至2020年间39例术后影像确认残留的WHO II级脑膜瘤患者,接受辅助IMRT(32例)或SRS(7例)。3年、5年、10年无进展生存率分别为81.1%、61.2%、44.6%,中位随访37个月。IMRT与SRS在3年及5年无进展生存率及放射性坏死方面无显著差异。
要点
- 39例次全切除后残留的WHO II级脑膜瘤患者接受辅助IMRT或SRS,3年无进展生存率为81.1%。
- IMRT组残留肿瘤体积显著大于SRS组(22.2 cm3 vs 6.3 cm3,p=0.004)。
- IMRT与SRS在3年及5年无进展生存率及放射性坏死方面无显著差异。
核心结论
- 在 homogeneous 患者队列中,辅助SRS或IMRT的3年肿瘤控制率可接受,IMRT与SRS在无进展生存或放射性坏死方面无显著差异。
研究设计与样本
- 回顾性研究,纳入1996至2020年间术后影像确认残留的WHO II级脑膜瘤患者39例,接受辅助IMRT(32例)或SRS(7例)。
主要发现
- 总体3年、5年、10年无进展生存率分别为81.1%、61.2%、44.6%,中位随访37个月。
- IMRT组残留肿瘤体积显著大于SRS组(22.2 cm3 vs 6.3 cm3,p=0.004)。
- IMRT与SRS的3年无进展生存率分别为81.1% vs 80.0%,5年分别为65.5% vs 40%(p=0.19)。
- 放射性坏死发生率IMRT组3/32例 vs SRS组0/7例(p=0.32)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Existing literature on adjuvant radiation after subtotal resection (STR) of WHO II meningiomas is limited by heterogenous patient cohorts, combining adjuvant and salvage radiation, gross total resection (GTR) and STR, primary radiation treatment vs. re-treatment, or grade II and III meningiomas, all of which have different expected outcomes. Tumor control estimates in a large homogenous patient cohort are needed to accurately counsel patients. METHODS: A retrospective review of patients that had immediate post-operative imaging-confirmed residual WHO grade II meningioma followed by either adjuvant intensity-modulated radiation therapy (IMRT) or stereotactic radiosurgery (SRS) between 1996 and 2020 was conducted. Kaplan-Meier survival analysis and log-rank test was used to assess progression-free survival (PFS). RESULTS: Thirty-nine patients met inclusion criteria (IMRT = 32; SRS = 7). Overall, the 3-, 5-, and 10-year PFS was 81.1%, 61.2%, and 44.6%, respectively. Median follow-up time was 37 months. When comparing IMRT and SRS cohorts, baseline characteristics did not differ significantly between groups, but significantly larger residual tumor volumes were treated with IMRT (22.2 cm3 vs. 6.3 cm3, p = 0.004). PFS was not significantly different between IMRT and SRS at 3 years (81.1% vs. 80.0%) or 5 years (65.5% vs. 40%) (p = 0.19). There was no significant difference in radiation necrosis between groups (IMRT = 3/32 patients vs. SRS = 0/7 patients, p = 0.32). CONCLUSION: Our homogenous patient cohort displayed acceptable control rates at 3 years using SRS or IMRT as adjuvant therapy. No significant difference in PFS or radiation necrosis was noted between patients treated with adjuvant IMRT versus SRS.
引用
- Petitt JC, Murayi R, El-Abtah ME, et al. Outcomes of adjuvant radiation treatment following subtotal resection of world health organization grade II meningiomas. J Neurooncol. 2024. PMID: 39538039. doi:10.1007/s11060-024-04878-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。